Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: the example of SARS‐CoV‐2 and monkeypox virus

alexandrossfakianakis shared this article with you from Inoreader Rapid and reliable inactivation protocols for the diagnostics of emerging viruses: the example of SARS‐CoV‐2 and monkeypox virus via Journal of Medical Virology ABSTRACT The emergence and sustained transmission of novel pathogens are exerting an increasing demand on the diagnostics sector worldwide, as seen with the ongoing SARS-CoV-2 pandemic and the more recent public health concern of monkeypox virus (MPXV) since May 2022. Appropriate and reliable viral inactivation measures are needed to ensure the safety of personnel handling these infectious samples. In the present study, 7 commercialized diagnosis buffers, heat [56°C and 60°C], and sodium dodecyl sulfate detergent [SDS; 2.0%, 1.0%, and 0.5% final concentrations] were tested against infectious SARS-CoV-2 and MPXV culture isolates on Vero cell culture. Cytopathic effects were observed up to 7 days post-inoculation and viral load evolution was measured by semi-quantitative PCR. WHO recommends an infectious titer reduction of at least 4 log10. As such, the data show efficacious SARS-CoV-2 inactivation by all investigated methods, with >6.0 log10 reduction. MPXV inactivation was also validated with all investigated methods with 6.9 log10 reduction, although some commercial buffers required a longer incubation period to yield complete inactivation. These results are valuable for facilities, notably those without BSL-3 capabilities, that need to implement rapid and reliable protocols common against both SARS-CoV-2 and MPXV. This article is protected by copyright. All rights reserved. View on Web

Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.